COVID-19 - September 27, 2021
Cyxone to use FDA pre-review for COVID-19 phase 2 trial
The company is expecting to communicate results from a recently concluded Phase 2 trial of its drug candidate Rabeximod in COVID-19 patients during the fourth quarter. The results were previously slated for the third quarter. The postponement is due to the company’s decision to leverage the U.S. Food and Drug Administration (FDA) initiative to pre-review […]
COVID-19 - September 22, 2021
Vicore Pharma obtains patent in the USA
Vicore Pharma has announced that the US Patent and Trademark Office (USPTO) has granted a patent covering the use of C21 to treat infections caused by Severe Acute Respiratory Syndrome (SARS) coronavirus (CoV), including SARS-CoV-2. “COVID-19 may be just a few mutations away from evading existing vaccines, and we know that even vaccinated people can […]
COVID-19 - September 16, 2021
Vaccine based on Abera’s technology shows neutralizing antibodies against Delta version
The vaccine platform developed by Abera Bioscience has been used in a collaboration between researchers at Johns Hopkins University School of Medicine (Baltimore, USA) and Vrije Universiteit (Amsterdam, the Netherlands) to produce and test a novel, nasal SARS-CoV-2 vaccine candidate. Previously published data have now been supplemented with further analyses showing that the vaccine candidate […]
COVID-19 - August 25, 2021
New study about how the COVID-19 virus binds to cell receptors
SARS-CoV-2 can attach to not one but two receptors on the host cell surfaces shows new Danish research. In 2003, the SARS epidemic caused panic in 26 countries on six continents, but only slightly more than 8,000 people developed SARS, resulting in less than 1,000 deaths. Almost 20 years later, SARS-CoV-2 struck, with more than […]
COVID-19 - August 24, 2021
AstraZeneca’s PROVENT trial met primary endpoint
AZD7442, a combination of two long-acting antibodies (LAAB), reduced the risk of developing symptomatic COVID-19 by 77%, compared to placebo. The Phase III trial accrued 25 cases of symptomatic COVID-19 at the primary analysis. There were no cases of severe COVID-19 or COVID-19-related deaths in those treated with AZD7442. In the placebo arm, there were […]
COVID-19 - August 17, 2021
NextCell files patent application for COVID-19 treatment
NextCell Pharma has announced that a patent application has been filed for the treatment of Sars-CoV-2 mediated severe pneumonia with ProTrans. NextCell increases the IP protection for the drug candidate ProTrans for the treatment of autoimmune diseases and inflammatory conditions. The latest patent application has is entitled; “Allogeneic Composition for Treatment off Covid-19”. By using […]
